A recent report in a form of an abstract (72), suggests that masitinib, a TKI that targets c-kit and other tyrosine kinases important in MC functions, decreased the rate of asthma exacerbations in patients with severe asthma that is not controlled with the use of oral corticosteroids. Here, KIT is linked to asthma.